Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + nimotuzumab induction chemotherapy vs concurrent chemoradiotherapy in high-risk locally advanced nasopharyngeal carcinoma
ChiCTR2600127595Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of serplulimab, nimotuzumab, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: 3-year event-free survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
serplulimabnimotuzumabgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600127595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127595.